In a mouse model, a short 3 h treatment with IL-1β, but not with TNF-α, activates NF-κB in a fraction of BM MM cells, while the IL-1β inhibitor Anakinra reduces their level of NF-κB activation. The gene discussed is NFKB1; the disease is Miyoshi myopathy.